Novartis AG

London - Acambis and Novartis were in a dispute over an experimental vaccine for yellow fever. The dispute arose over non-performance from a 1999 deal by predecessor companies acquired by Novartis. Acambis had US sales rights to the Arilvax vaccine and had previously completed Phase 3 clinical trials with a view to applying for a license in the US. Novartis has agreed to pay $19 million to settle the dispute over the Arilvax yellow fever vaccine. (Sep-12-06) [REUTERS]

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.